Nektar Therapeutics today announced that it has successfully closed the divestiture of specific Nektar pulmonary delivery assets, technology, and intellectual property to Novartis for $115 million in cash. The transaction was completed on December 31, 2008, 2008.
The details can be read here.
No comments:
Post a Comment